Study With Pazopanib in Combination With Cisplatin (CDDP) in Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The aim of this research is to evaluate the potential interest of an association of
Pazopanib, a multi-tyrosine kinase inhibitor, and cisplatin.
As cisplatin has marketing approval for several cancers (ovarian, testicle, bladder,
esophagus, endometrium, lung, stomach, head and neck cancer (HNC)), and in order to have a
rapid evaluation of this combination, we will evaluate the combination in any patient whose
tumors is known to be sensible to cisplatin (except tumors at risk of bleeding).
This study is a classical phase 1 trial of pazopanib and 3-weekly cisplatin association. It
will allow for optimal dose selection and pharmacokinetic analysis. It is planed to include
around 38 patients, enriching the optimal tolerated regimen (OTR) level only with a cohort of
triple negative breast cancer patients. If the association is proven to be feasible, we will
then move to a specific phase II study in triple negative breast cancer patients.